Clinical Trials

Efficacy and Safety of RE-021, A Dual Endothelin Receptor and Angiotensin Receptor Blocker, In Patients With Focal Segmental Glomerulosclerosis (FSGS): A Randomized, Double-Blind, Active-Control, Dose-Escalation Study


Research Study Number:
PRO00004870

Short Title:
Duet study

Division:
Nephrology

Study Status:
Enrolling